Résumé
Pancreatic ductal adenocarcinoma is a devastating and malignant disease,with a five year survival rate of less than 5％.Despite our improvement of surgical techniques and adjuvant medical therapy,most patients with pancreatic cancer have a dismal prognosis.The poor outcome of this tumor is associated with a high degree of drug resistance.Recently,the emerging knowledge of the molecular basis of pancreatic cancer may provide new avenues to get better prognostication for individual patients based on the molecular profile of obtained tissue by a biopsy or from resected specimens.So some novel drugs targeting signal pathway both within cancer cell and cancer microenvironment are undergoing preclinical.This article reviews the different targeted approaches in pancreatic cancer.